This month I explore the recent surge in M&A activity, where 2025 ranks from a historical perspective, and evaluate the acquisition potential of the coverage ecosystem.

A takeout at $105 per share represents a more than 60% premium to the average closing price of the last month.

A look at what to expect when companies report third-quarter 2025 operating results beginning in late October and extending through November.

This month I share insights into how I might temporarily downsize or exit Finch Trades positions if the market keeps melting up.

Wall Street hates the exclusive license to Freenome's liquid screen for colon cancer. Meanwhile, the business roared to $811 million in revenue and a net loss of just $1 million, crushing estimates.

A look at what to expect when companies report second-quarter 2025 operating results beginning in late July and extending through August.

The company's blood-based colon cancer screening tool is likely to fall short of Medicare coverage requirements, which recommend specificity of 90% or above. But it's not so simple.

The business has generated $323 million in cash from operations in the last year, but investors might cut short their celebration if recent and upcoming launches falter.

As previously communicated, I made a series of short-term investments during Q1 2025 earnings season.

This is one of multiple short-term investments I expect to make during Q1 2025 earnings season.

A look at what to expect when companies report first-quarter 2025 operating results beginning in late April and extending through May.

Product costs grew faster than revenue in 2024, but the launch of Cologuard Plus should improve margins this year.

The business is objectively healthier than ever based on operating efficiency metrics, but several unexpected headwinds will result in weaker than expected growth for 2024.

The business has positive operating cash flow. It could begin generating operating income in 2025 or 2026, depending on how aggressive management wants to be – and if its internal analytics are correct.

The cancer diagnostics company reported year-over-year revenue growth of just 6.5% to start 2024 and made heavier investments, which drove key operating metric down.

The number of patients eligible for their second or third Cologuard screening will increase from an estimated 1.4 million in 2023 to 2.0 million in 2024. Revenue from rescreens could grow at least 85% from 2022 to 2025.

The multi-omics diagnostics leader is trending in the right direction on nearly every important metric. It'll need to keep the momentum going ahead of multiple important launches.

The Cologuard leader raised guidance for full-year 2023 revenue and adjusted EBITDA. This is a high-quality growth stock and we believe investors can feel comfortable paying up now for future growth, but shares are likely overvalued based on expected 2023 or 2024 financial performance.

The BLUE-C study of a next-generation version of Cologuard met all primary endpoints and reduced false positives by 30% compared to the existing product. However, there was no meaningful improvement on precancerous lesion detection.

The genetic diagnostics leader raised full-year 2023 revenue guidance, now expects to achieve positive free cash flow in 2023 instead of 2024, and is on pace to achieve positive full-year 2024 operating income according to our modeling.

The business grew Screening revenue 30% in 2022 from the year-ago period, but initial full-year 2023 revenue guidance expects the segment to grow "only" 18% at the midpoint. This is likely an underestimate.

Results from the multi-target stool DNA (MT-sDNA) portion of the BLUE-C study in colon cancer screening are expected in early 2023. A disappointing readout could crush the stock's rally, or lead to a short-term pop if the market gets carried away.

Quick updates for Coherus BioSciences, Exact Sciences, Krystal Biotech, and Selecta Biosciences.

Liquid biopsy screening tests for colorectal cancer (colon cancer) remain challenged in the competitive landscape, even with high adherence rates.

Management raised full-year 2022 revenue guidance and slashed operating expenses guidance. The new guidance ranges could still be too conservative.

This article explores Solt DB Invest forecast and modeling in greater detail, including current expectations for revenue and profitability ramps.

Solt DB Invest initiates coverage of Exact Sciences, which is the 11th company in our coverage ecosystem. This article explains the competitive landscape in multi-cancer early detection (MCED) diagnostics.